As we bid farewell to the past and embrace the future, ConFlow MedTech is celebrating several milestones. Recently, the company announced the successful completion of its Round A financing, securing nearly 60 million RMB. This phase of funding was led by Tai Yu Ankang and co-invested by Tai Kun Fund. The primary allocation of these funds will support ConFlow MedTech's preclinical and registered clinical trials for its research projects, as well as the independent research and development and commercialization of new medical products. This financial support will significantly enhance the R&D efforts for ConFlow MedTech's innovative medical products.

  ConFlow MedTech is devoted to advancing innovative cardiovascular medical devices, primarily focusing on research, development, production, and industrialization operations. Our aim is to establish ourselves as a leading manufacturer of groundbreaking global-impact products through continuous independent research and the clinical application of cutting-edge technology.  

  Our management team brings over a decade of experience in structural heart disease, comprising professional experts in R&D, clinical quality assurance, and marketing. Our company boasts a portfolio of more than 20 international PCT, invention, and utility model patents.  

Nestled in the heart of Songjiang Science and Technology City, Shanghai Lingang Group proudly occupies a spacious 2,200-square-meter complex. This facility boasts a pristine environment featuring a 10k-grade clean workshop, well-equipped laboratories, machining platforms, and modern office spaces. While advancing our shunt project into clinical trials, ConFlow MedTech actively explores innovative interventional products for congenital heart disease and valve products through animal experiments. Our dedication lies in creating a unique and innovative platform for structural heart disease research and production.

The FreeFlow® percutaneous atrial septal shunt system has successfully undergone multiple clinical trials, leading to significant improvements in clinical symptoms and heart function among postoperative heart failure patients. Its clinical efficacy is noteworthy, offering a novel therapeutic approach for heart failure patients beyond conventional drug treatments. FreeFlow® represents China's inaugural atrial septal shunt system featuring rapid endothelialization through a polymer membrane and secondary recycling. Its distinctive elliptical design minimizes implant volume and allows for compatibility with a smaller delivery system. This technology has been granted multiple patents and boasts comprehensive independent intellectual property rights, establishing it as a truly original Chinese research innovation.

Ms. Chen Xiumin, Founder of ConFlow MedTech, asserts that China's cardiovascular medical sector is experiencing rapid growth after a decade of extensive exploration and knowledge accumulation. The country, alongside local governments, has implemented numerous policies and incentives to promote the advancement of medical technology and foster independent R&D of innovative medical devices.

Building upon a wealth of clinical diagnostic and treatment expertise, Chinese healthcare professionals have ingeniously crafted multiple treatment strategies and patented technologies by integrating various clinical challenges and engineering design principles. Chinese R&D engineers, possessing practical experience in both domestic and international innovative product development, demonstrate proficiency across the entire spectrum of R&D project technology and product development.

Chinese suppliers have made significant strides in enhancing raw materials, processing techniques, supporting equipment technology, and product quality through continuous collaboration with major domestic and international manufacturers. With the impetus provided by bulk medical consumables procurement policies, the Chinese capital market has delved deeper into identifying high-quality projects characterized by original research and innovation.

In this juncture, ConFlow MedTech, a China-based cardiovascular innovative medical device company with a global perspective, is poised to leverage this favorable environment. The company adopts a pragmatic and innovative approach, leveraging its professional R&D team and years of experience in clinical transformation. In the ongoing wave of technological innovation, ConFlow MedTech is destined to carve a niche for itself and achieve even greater milestones in the future.

Dr. Ji Tianrong, Founder of Tiger Yeah  Capital, has emphasized the immense prevalence of structural heart disease patients in China, along with the significant unmet clinical demand. Concurrently, the field of structural heart disease medical devices is experiencing rapid growth, offering various innovative avenues and substantial potential for diverse product development. Among the multitude of startups, ConFlow MedTech distinguishes itself by establishing close collaborations with clinical experts and engaging in practical clinical applications. The team has successfully developed a range of innovative and well-established products, which is indeed commendable. Medical devices, particularly those related to cardiovascular intervention therapy, represent the focal points of TigerYeah Capital's  investment strategy. We anticipate that our partnership with ConFlow MedTech will expedite product launches and enable us to promptly serve a substantial population of patients with structural heart diseases.

The Taikun Fund project leader emphasized that cardiovascular disease remains a pivotal focus for cutting-edge medical device research and development. With China's aging population accelerating, there's a rising incidence of cardiovascular diseases and a substantial unmet clinical demand. ConFlow MedTech, led by a seasoned industry team, has made impressive strides since its inception. The company has established a robust R&D pipeline through independent research and research conversion. Their flagship product, FreeFlow®, has demonstrated significant clinical efficacy and made steady progress. As investors in this funding phase, we will closely monitor ConFlow MedTech's market development and demands. We're committed to supporting the advancement of multiple innovative products and aiding ConFlow MedTech in becoming a preeminent player in the cardiovascular medical device industry.